Meningococcal vaccine

Known as: Meningococcal vaccines, Vaccine, Meningococcal, Vaccines, Meningococcal 
Any vaccine derived from Neisseria meningitidis whether in whole-cell or acellular form used for prophylaxis against meningitis.
National Institutes of Health

Related topics

Related topics

23 relations

Narrower (10)

4CMenB vaccineBivalent Meningococcal VaccineMenACWYMenACWY-CRM vaccine
(More)

Broader (2)

Bacterial VaccinesMeningococcal vaccine component
In BloodMeningitis vaccineNeisseria meningitidis vaccineProcess of secretion
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial
BACKGROUND Meningococcal conjugate vaccines protect individuals directly, but can also confer herd protection by interrupting… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The Meningococcal Vaccine Candidate Neisserial Surface Protein A (NspA) Binds to Factor H and Enhances Meningococcal Resistance to Complement
Complement forms an important arm of innate immunity against invasive meningococcal infections. Binding of the alternative… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
CONTEXT Immunization with a meningococcal tetravalent (serogroup ACWY) glycoconjugate vaccine is recommended for all US… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance.
Neisseria meningitidis binds factor H (fH), a key regulator of the alternative complement pathway. A approximately 29 kD fH… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
In January 2005, a tetravalent meningococcal polysaccharide-protein conjugate vaccine ([MCV4] Menactra, manufactured by Sanofi… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.
Meningococcal C conjugate (MCC) vaccines were licensed on the basis of serological correlates of protection without efficacy data… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.
The introduction of meningococcal C conjugate (MCC) vaccine in the UK in November 1999 as a routine 3 dose infant immunisation… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Effectiveness of influenza vaccine in health care professionals: a randomized trial.
CONTEXT Data are limited and conflicting regarding the effectiveness of influenza vaccine in health care professionals… (More)
  • figure I
  • table 1
  • table 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.
CONTEXT Meningococcal disease occurs worldwide, and serogroup B disease accounts for a large proportion of cases. Although… (More)
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.
The antibody kinetics in sera from 27 adults after three doses of the Norwegian group B meningococcal outer membrane vesicle (OMV… (More)
Is this relevant?